As standard chemotherapy and even novel anti-angiogenic treatments have largely failed patients stricken with angiosarcoma, strategies for exploiting MYC dependency in angiosarcoma tumors are an attractive disease-specific goal. This evidence concerns the gene MYC and angiosarcoma.